The junctional component does not typically extend beyond the dermal component, i.e
Mounjaro (tirzepatide for T2DM) and Zepbound (tirzepatide for obesity) from Eli Lilly are growing at the fastest CAGR, driven by the dual GLP-1/GIP receptor agonist mechanism that has consistently demonstrated superior weight loss outcomes versus semaglutide in head-to-head clinical comparisons
Among PUFAs, arachidonic acid (AA), adrenergic acid (AdA) and phosphatidylethanolamine (PE) are the main substrates that undergo oxidation [43]
In previous studies, we detected that SPT may have a negative impact on fetal skeletal muscle development during the prenatal period (Turgut et al., 2025a)
Consider Comorbid Health Conditions Patients with weight-related comorbidities such as type 2 diabetes, sleep apnea, or heart disease may be advised to continue GLP-1 therapy to manage these conditions in conjunction with weight loss
Fasting and cancer: molecular mechanisms and clinical application